Sun Pharmaceutical Industries Ltd.,
SUN HOUSE, CTS No. 201 B/1,
Western Express Highway, Goregaon (E),
Mumbai 400063, India
Tel.: (91-22) 4324 4324 Fax.: (91-22) 4324 4343
CIN: L24230GJ1993PLC019050
www.sunpharma.com

25 April 2017.

National Stock Exchange of India Ltd,
Exchange Plaza, 5th Floor,
Plot No. C/1, G Block,
Bandra Kurla Complex,
Bandra (East),
Mumbai – 400 051.

BSE Limited,
Market Operations Dept.
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai - 400 001.

Dear Sirs,

Sub: Press Release

We are pleased to enclose herewith our Press Release relating to the Roll-out of Malaria Demonstration Project by FDEC, which we shall be releasing after sending this letter to you. This is for your information and records.

Thanking you,

Yours faithfully,
For Sun Pharmaceutical Industries Ltd

A. I. Bhuta

Ashok I. Bhuta
Compliance Officer

Encl: as above

Foundation for Disease Elimination and Control of India
MEDP Office, Room No - 319 (A), Second Floor, National Institute for Research in Tribal Health (NIRTH), (ICMR), Jabalpur - 482003, Madhya Pradesh, India. M: –91 9414049739 | 8120955007

FOR IMMEDIATE RELEASE

FDEC commences roll-out of *Malaria demonstration* project

Phase 1 of demonstration project in Madhya Pradesh on World Malaria Day

JABALPUR & MUMBAI – APRIL 25, 2017: The Foundation for Disease Elimination and Control of India (FDEC-INDIA), Indian Council of Medical Research and Govt. of Madhya Pradesh today announced Phase 1 roll-out of Malaria demonstration project in Mandla, Madhya Pradesh. This Phase will focus on community awareness and education programs among the community residents in Mandla. The launch was announced by Minister of State for Health Fagan Singh Kuleste at a function held in Kalpi Guest House to coincide with World Malaria Day. The Foundation for Disease Elimination and Control of India (FDEC-INDIA) has been established by Sun Pharmaceutical Industries Ltd. *(Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715, "Sun Pharma" including its subsidiaries or associate companies)* for disease elimination and control initiatives undertaken through its CSR programme.

National Institute for Research in Tribal Health (NIRTH)/ICMR, Govt of MP and FDEC-India are jointly accomplishing the goals of malaria elimination in Mandla district and prevent re-introduction by use of vector control indoor residual spray and/or use of insecticide treated long-lasting bednets (LLINs) and case management (rapid on-the-spot diagnosis and prompt treatment) as per national and/or WHO norms of malaria elimination efforts. FDEC-India is responsible for implementation of the Project in collaboration with NIRTH/ICMR, Govt of MP and all appropriate stakeholders. It will execute the malaria elimination project over a span of 3 to 5 years covering over 1,200 villages in Mandla district.

As part of the Phase 1 roll-out, in addition to the community awareness programmes, FDEC will begin intense case & surveillance-based malaria control using RDTs, ACTs, LLIN bednets and insecticide spray. Over the next two years, it will focus on sensitizing local communities about detection and treatment requirements to keep them malaria free while continuing intense surveillance-based malaria control and community-based awareness & education programs. The Foundation will also undertake measures to prevent re-introduction of malaria into Mandla district from outside areas and mobilize communities to 'look' for introduction of new cases by travellers from neighbouring districts.

According to Dr. S.Y. Quraishi, Chairman of the Foundation for Disease Elimination and Control of India (FDEC-India), *"We have launched the ground work for eliminating malaria in Mandla today, which is World Malaria Day. Malaria elimination has been recognized as a global priority and a target of 2030 has been established for elimination. The Public-Private-Partnership between FDEC-India, ICMR and Govt. of MP is an important collaboration to meet health challenges and I hope other organizations will join FDEC-India in this and future health initiatives"*

According to Mrs. Gauri Singh, Principal Secretary Health, Government of Madhya Pradesh, "The Govt. of MP has established a Public-Private-Partnership with FDEC-India and ICMR for demonstrating malaria elimination is possible. Our goal is to eliminate malaria from 1233 villages of district Mandla. Today, on World Malaria Day on April 25, we start community engagement for this an important collaboration to meet an important health challenge. Malaria elimination has been recognized as a global priority and a target of 2030 has been established for elimination. The community participation is essential for success of this initiative, and today's event demonstrate our commitment to work hand-in-hand with individuals and communities in Mandla."

According to Dr. Neeru Singh, Director, National Institute for Research in Tribal Health, Indian Council of Medical Research, Department of Health Research, Ministry of Health and Family Welfare, *"The Community reach out for our collaborative project with Govt. of MP and FDEC-India on World Malaria Day shows commitment of parties of this Public-Private-Partnership for demonstrating malaria elimination is possible. Our goal is to provide better intervention in hard to reach areas to eliminate malaria from underprivileged communities residing in 1233 villages of district Mandla. India launched National framework on Malaria Elimination from the country by 2030 in phased manner. We have started from the remoted part to serve the underserved community. For malaria elimination, the participation of individuals and community leader is essential. As part of our strategy, we will stay engaged with communities throughout the district and inform them about project goals, progress of the project, and seek feedback"*

The Malaria Free India initiative was announced in 2016 as part of the broader MOU signed between ICMR and Sun Pharma for development of translational health sciences and disease control & elimination. ICMR's National Institute for Research in Tribal Health is one of it's permanent national institute situated in Jabalpur, Madhya Pradesh with the mandate to plan, conduct and coordinate research on specific health problems and health needs of the tribals. The Institute is also WHO Collaborative Centre for the Health of the Indigenous populations.

Government of India has shown strong regional leadership on Malaria, in helping to guide the region towards endorsement of the Asia Pacific Leaders Malaria Alliance (hereinafter referred to as "APLMA") Roadmap in November 2015. Within just three months, the Ministry of Health and Family Welfare launched "The National Framework for Malaria Elimination in India" and set the target of elimination of malaria in India as 2030. According to WHO estimates, India contributes about 70% of malaria cases in South East Asia Regional countries. India has the highest number of deaths outside the African continent, with approximately 181.3 million at high risk and 997.4 million people at low and high risk. Malaria has been shown to impede development, saving and investment, worker productivity, and per-capita gross domestic product. Malaria has also been shown to promote school and workplace absenteeism. It has been shown that there is a strong correlation between malaria and poverty, and malaria endemic countries have lower rates of economic growth.

ABOUT FOUNDATION FOR DISEASE ELIMINATION AND CONTROL OF INDIA (CIN: U85190MH2016NPL286097)

FDEC-India, has been established by Sun Pharma as part of its Corporate Social Responsibility initiative. It is a not-for-profit Company registered under Section-8 of the Companies Act,2013) with its registered office at Sun House, Plot No. 201 B/1, Western Express Highway, Goregaon (East), Mumbai- 400063. The Foundation is governed by Board of Directors (Dr. SY Quraishi (Chair), Dr. KK Agarwal, Dr. Altaf Lal, Dr. Nilima Kshirsagar and Mr, Azadar Khan) and supported by Advisory Board Members (Mr. Anil Raghvan, Dr. Srinath Reddy, Dr. P.L Joshi, and, Dr. Jacob John).

ABOUT SUN PHARMACEUTICAL INDUSTRIES LTD (CIN - L24230GJ1993PLC019050)

Sun Pharma is the world's fifth largest specialty generic pharmaceutical company and India's top pharmaceutical company. A vertically integrated business, economies of scale and an extremely skilled team enable us to deliver quality products in a timely manner at affordable prices. It provides high-quality, affordable medicines trusted by customers and patients in over 150 countries across the world. Sun Pharma's global presence is supported by 47 manufacturing facilities spread across 6 continents, R&D centres across the globe and a multi-cultural workforce comprising over 50 nationalities. The consolidated revenues for 12 months ending March 2016 are approximately US$ 4.3 billion, of which US contributes US$ 2.1 billion. In India, the company enjoys leadership across 12 different classes of doctors with 32 brands featuring amongst top 300 pharmaceutical brands in India. Its footprint across emerging markets covers over 100 markets and 6 markets in Western Europe. Its Global Consumer Healthcare business is ranked amongst Top 10 across 4 global markets. Its API business footprint is strengthened through 14 world class API manufacturing facilities across the globe. Sun Pharma fosters excellence through innovation supported by strong R&D capabilities comprising about 2,000 scientists and R&D investments of over 8% of annual revenues.

For further information please visit www.sunpharma.com Follow us on Twitter @SunPharma_Live

ABOUT INDIAN COUNCIL OF MEDICAL RESEARCH

The Indian Council of Medical Research (ICMR), New Delhi, the apex body in India for the formulation, coordination and promotion of biomedical research, is one of the oldest medical research bodies in the world. The Government of India set up the Indian Research Fund Association (IRFA) with the specific objective of sponsoring and coordinating medical research in the country. After independence, several important changes were made in the organisation and the activities of the IRFA. It was redesignated in 1949 as the Indian Council of Medical Research (ICMR) with considerably expanded scope of functions. The ICMR is funded by the Government of India through the Department of Health Research, Ministry of Health & Family Welfare. The Council's research priorities coincide with the National health priorities such as control and management of communicable diseases, fertility control, maternal and child health, control of nutritional disorders, developing alternative strategies for health care delivery, containment within safety limits of environmental and occupational health problems; research on major non-communicable diseases like cancer, cardiovascular diseases, blindness, diabetes and other metabolic and haematological disorders; mental health research and drug research (including traditional remedies). All these efforts are undertaken with a view to reduce the total burden of disease and to promote health and well-being of the population. The Governing Body of the Council is presided over by the Union Health Minister. It is assisted in scientific and technical matters by a Scientific Advisory Board comprising eminent experts in different biomedical disciplines.

FOR FURTHER DETAILS PLEASE CONTACT SUN PHARMA
CORPORATE COMMUNICATIONS
Frederick Castro |+91 9920665176 | frederick.castro@sunpharma.com

INVESTOR RELATIONS CONTACT
Nimish Desai | +91 9820330182 | nimish.desai@sunpharma.com